PharmGen Science, Inc. (004720.KS)
KRW 4370.0
(-1.47%)
KRW 4370.0
(-1.47%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 9.12 Billion KRW | -90.4% |
| 2022 | 95.02 Billion KRW | 123.62% |
| 2021 | 42.49 Billion KRW | 198.74% |
| 2020 | 14.22 Billion KRW | 1098.04% |
| 2019 | 1.18 Billion KRW | -76.19% |
| 2018 | 4.98 Billion KRW | -17.05% |
| 2017 | 6.01 Billion KRW | 24.32% |
| 2016 | 4.83 Billion KRW | 6.87% |
| 2015 | 4.52 Billion KRW | 225.33% |
| 2014 | -3.6 Billion KRW | -5.22% |
| 2013 | -3.43 Billion KRW | 31.81% |
| 2012 | -5.03 Billion KRW | -29.05% |
| 2011 | -3.89 Billion KRW | -233.43% |
| 2010 | 2.92 Billion KRW | -2.53% |
| 2009 | 2.99 Billion KRW | -21.35% |
| 2008 | 3.81 Billion KRW | 42.98% |
| 2007 | 2.66 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 2.71 Billion KRW | -9.73% |
| 2024 Q1 | 3.01 Billion KRW | -24.96% |
| 2023 Q4 | 4.01 Billion KRW | 440.71% |
| 2023 Q1 | 1.94 Billion KRW | -97.79% |
| 2023 Q2 | 2.42 Billion KRW | 24.58% |
| 2023 Q3 | 742.19 Million KRW | -69.39% |
| 2023 FY | 9.12 Billion KRW | -90.4% |
| 2022 Q4 | 87.91 Billion KRW | 7002.19% |
| 2022 Q3 | 1.23 Billion KRW | 13.05% |
| 2022 Q2 | 1.09 Billion KRW | -66.01% |
| 2022 Q1 | 3.22 Billion KRW | 330.57% |
| 2022 FY | 95.02 Billion KRW | 123.62% |
| 2021 Q3 | 865.24 Million KRW | 116.45% |
| 2021 Q2 | -5.25 Billion KRW | -277.87% |
| 2021 Q1 | -1.39 Billion KRW | 22.19% |
| 2021 FY | 42.49 Billion KRW | 198.74% |
| 2021 Q4 | 748.1 Million KRW | -13.54% |
| 2020 Q2 | 1.89 Billion KRW | 312.88% |
| 2020 FY | 14.22 Billion KRW | 1098.04% |
| 2020 Q4 | -1.78 Billion KRW | -1641.25% |
| 2020 Q3 | 116.06 Million KRW | -93.86% |
| 2020 Q1 | -888.43 Million KRW | -51.38% |
| 2019 Q4 | -586.9 Million KRW | -932.54% |
| 2019 Q2 | 1.11 Billion KRW | 87.26% |
| 2019 FY | 1.18 Billion KRW | -76.19% |
| 2019 Q1 | 593.09 Million KRW | -59.91% |
| 2019 Q3 | 70.49 Million KRW | -93.65% |
| 2018 Q4 | 1.47 Billion KRW | 1077.94% |
| 2018 FY | 4.98 Billion KRW | -17.05% |
| 2018 Q2 | 2.12 Billion KRW | 69.11% |
| 2018 Q3 | 125.57 Million KRW | -94.09% |
| 2018 Q1 | 1.25 Billion KRW | -14.4% |
| 2017 Q2 | 1.59 Billion KRW | 68.43% |
| 2017 FY | 6.01 Billion KRW | 24.32% |
| 2017 Q4 | 1.46 Billion KRW | -26.68% |
| 2017 Q3 | 2 Billion KRW | 25.56% |
| 2017 Q1 | 946.64 Million KRW | -53.78% |
| 2016 Q1 | 1.59 Billion KRW | 1442.91% |
| 2016 Q3 | 684.94 Million KRW | 34.25% |
| 2016 Q4 | 2.04 Billion KRW | 198.99% |
| 2016 Q2 | 510.19 Million KRW | -67.96% |
| 2016 FY | 4.83 Billion KRW | 6.87% |
| 2015 Q4 | 103.19 Million KRW | -84.7% |
| 2015 FY | 4.52 Billion KRW | 225.33% |
| 2015 Q3 | 674.47 Million KRW | -67.83% |
| 2015 Q2 | 2.09 Billion KRW | 27.06% |
| 2015 Q1 | 1.65 Billion KRW | 181.98% |
| 2014 Q3 | -739.23 Million KRW | -62.84% |
| 2014 Q2 | -453.97 Million KRW | -12.39% |
| 2014 FY | -3.6 Billion KRW | -5.22% |
| 2014 Q1 | -403.91 Million KRW | 81.24% |
| 2014 Q4 | -2.01 Billion KRW | -172.29% |
| 2013 Q3 | -971.02 Million KRW | -1079.35% |
| 2013 Q4 | -2.15 Billion KRW | -121.72% |
| 2013 FY | -3.43 Billion KRW | 31.81% |
| 2013 Q1 | -433.31 Million KRW | 92.28% |
| 2013 Q2 | 99.15 Million KRW | 122.88% |
| 2012 Q4 | -5.61 Billion KRW | -5285.91% |
| 2012 FY | -5.03 Billion KRW | -29.05% |
| 2012 Q2 | -455.01 Million KRW | -211.27% |
| 2012 Q3 | -104.2 Million KRW | 77.1% |
| 2012 Q1 | 408.91 Million KRW | 141.78% |
| 2011 Q1 | 1.53 Billion KRW | 5330.54% |
| 2011 Q4 | -978.76 Million KRW | -162.45% |
| 2011 FY | -3.89 Billion KRW | -233.43% |
| 2011 Q2 | -6.1 Billion KRW | -498.28% |
| 2011 Q3 | 1.56 Billion KRW | 125.69% |
| 2010 Q3 | 750.05 Million KRW | -50.09% |
| 2010 Q2 | 1.5 Billion KRW | 261.63% |
| 2010 Q1 | 415.56 Million KRW | 52.41% |
| 2010 FY | 2.92 Billion KRW | -2.53% |
| 2010 Q4 | 28.2 Million KRW | -96.24% |
| 2009 Q2 | -34.23 Million KRW | -104.96% |
| 2009 Q4 | 272.66 Million KRW | -86.82% |
| 2009 Q3 | 2.06 Billion KRW | 6143.65% |
| 2009 Q1 | 690.34 Million KRW | 157.77% |
| 2009 FY | 2.99 Billion KRW | -21.35% |
| 2008 Q1 | 2.54 Billion KRW | 1486.14% |
| 2008 Q3 | 1.43 Billion KRW | 39.6% |
| 2008 Q4 | -1.19 Billion KRW | -183.28% |
| 2008 FY | 3.81 Billion KRW | 42.98% |
| 2008 Q2 | 1.02 Billion KRW | -59.6% |
| 2007 Q4 | -183.52 Million KRW | 76.8% |
| 2007 Q2 | 1.18 Billion KRW | -51.98% |
| 2007 FY | 2.66 Billion KRW | 0.0% |
| 2007 Q3 | -791.15 Million KRW | -166.99% |
| 2007 Q1 | 2.45 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Daewoong Co., Ltd. | 195.87 Billion KRW | 95.34% |
| Wooridul Huebrain Limited | -11.4 Billion KRW | 180.034% |